The Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) on June 10th, 2022 (day 2) will review a Biologic license application (BLA) submitted by Bluebird Bio; BLA 125717 for betibeglogene autotemcel for the treatment of patients with β-thalassemia who require regular red blood cell transfusions cross all genotypes who require regular red blood cell (RBC).
Back to All Events
Earlier Event: June 9
Cellular, Tissue, and Gene Therapies Advisory Committee
Later Event: June 14
Vaccines and Related Biological Products Advisory Committee